Tomasz Jankowski

Suggest Changes
Learn More
PURPOSE P95HER2 (p95) is a truncated form of the HER2, which lacks the trastuzumab-binding site and contains a hyperactive kinase domain. Previously, an optimal clinical cutoff of p95 expression for(More)
586 Background: Expression of p95 in HER2-positive breast cancer patients is potentially a major determinant of trastuzumab resistance because p95 lacks the trastuzumab binding site while retaining(More)